ABC | Volume 111, Nº4, Octuber 2018

Original Article Yang et al ApoJ in neointimal hyperplasia Arq Bras Cardiol. 2018; 111(4):562-568 1. Sharma PK, Chhatriwalla AK, Cohen DJ, Jang JS, Baweja P, Gosch K, et al. Predicting long-term bleeding after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2017;89(2):199-206. 2. Lee JY, Park DW, Kim YH, Yun SC, Kim WJ, Kang SJ, et al. Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. J Am Coll Cardiol. 2011;57(12):1349-58. 3. Shannan B, Seifert M, Boothman DA, Tilgen W, Reichrath J. Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. J Mol Histol. 2006;37(5-7):183-8. 4. Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res. 2006;40(12):1324-34. 5. Park S, Mathis KW, Lee IK. The physiological roles of apolipoprotein J/ clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15(1):45-53. 6. Gelissen IC, Hochgrebe T, Wilson MR, Easterbrook-Smith SB, Jessup W, Dean RT, et al. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem J. 1998;331(Pt 1):231-7. 7. Ishikawa Y, Akasaka Y, Ishii T, Komiyama K, Masuda S, Asuwa N, et al. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol. 1998;18(4):665-72. 8. NavabM,AnantharamaiahGM,ReddyST,VanLentenBJ,WagnerAC,Hama S, et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005;25(9):1932-7. 9. MiyataM, Biro S, Kaieda H, EtoH, Orihara K, Kihara T, et al. Apolipoprotein J/clusterin is induced in vascular smooth muscle cells after vascular injury. Circulation. 2001;104(12):1407-12. 10. Millis AJ, Luciani M, McCue HM, Rosenberg ME, Moulson CL. Clusterin regulates vascular smooth muscle cell nodule formation and migration. J Cell Physiol. 2001;186(2):210-9. 11. Shirasawa T, Miyata M, Eto H, Hamada N, Akasaki Y, Miyauchi T, et al. Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury. J Atheroscler Thromb. 2009;16(6):772-81. 12. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ, Kim JK, et al. Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29(10):1558-64. 13. Preusch MR, Vanakaris A, Bea F, Ieronimakis N, Shimizu T, Konstandin M, et al. Rosuvastatin reduces neointima formation in a rat model of balloon injury. Eur J Med Res. 2010;15(11):461-7. 14. Garcia-Rodriguez S, Arias-Santiago S, Perandres-Lopez R, Orgaz-Molina J, Castellote L, Buendia-Eisman A, et al. Decreased plasma levels of clusterin in patients with psoriasis. Actas Dermosifiliogr. 2013;104(6):497-503. 15. Yanni AE, Agrogiannis G, Gkekas C, Perrea D. Clusterin/Apolipoprotein J immunolocalization on carotid artery is affected by TNF-alpha, cigarette smoking and anti-platelet treatment. Lipids HealthDis. 2014 Apr 23;13:70. 16. WitteDP, AronowBJ, StaudermanML, StuartWD, ClayMA, Gruppo RA, et al. Plateletactivationreleasesmegakaryocyte-synthesizedapolipoproteinJ,ahighly abundant protein in atheromatous lesions. Am J Pathol. 1993;143(3):763-73. 17. Sivamurthy N, Stone DH, Logerfo FW, Quist WC. Apolipoprotein J inhibits the migration, adhesion, and proliferation of vascular smooth muscle cells. J Vasc Surg. 2001;34(4):716-23. 18. Foglio E, Puddighinu G, Fasanaro P, D’Arcangelo D, Perrone GA, Mocini D, et al. Exosomal clusterin, identified in the pericardial fluid, improves myocardialperformancefollowingMIthroughepicardialactivation,enhanced arteriogenesisandreducedapoptosis.IntJCardiol.2015Oct15;197:333-47. 19. Van Dijk A, Vermond RA, Krijnen PA, Juffermans LJ, Hahn NE, Makker SP, et al. Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest. 2010;40(10):893-902. 20. Lee YN, Shim YJ, Kang BH, Park JJ, Min BH. Over-expression of human clusterin increases stress resistance and extends lifespan in Drosophila melanogaster. Biochem Biophys Res Commun. 2012;420(4):851-6. 21. Pereira RM, Mekary RA, da Cruz Rodrigues KC, Anaruma CP, Ropelle ER, da Silva AS, et al. Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes. Heart Fail Rev. 2018;23(1):123-9. 22. vanderHarstP,GroenewegenHC,RoksAJ,BuikemaH,ZijlstraF,vanGilstWH, etal.RosuvastatinattenuatesangiotensinII-inducedneointimalformationafter stent implantation in the rat. Coron ArteryDis. 2008;19(1):47-53. 23. Kappert K, LeppanenO, Paulsson J, Furuhashi M, CarlssonMA, Heldin CH, et al. Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury. J Acquir Immune Defic Syndr. 2006;43(4):383-92. 24. LuanZ,ChaseAJ,NewbyAC.Statinsinhibitsecretionofmetalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23(5):769-75. 25. Miwa Y, Takahashi-Yanaga F, Morimoto S, Sasaguri T. Involvement of clusterin in 15-deoxy-delta12,14-prostaglandin J2-induced vascular smooth muscle cell differentiation. BiochemBiophys Res Commun. 2004;319(1):163-8. References analysis: Yang N, Dong B; Critical revision of the manuscript for intellectual content: Yang N, Dong B, Yang J, Li Y, Qin Q. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding This work was funded by the Health and Family Planning Commission, Science and Technology of Tianjin, (Award N°. 2015KR07), and the Tianjin Health Industry (Award N°. 13KG131). Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This study was approved by the Ethics Committee on Animal Experiments of the Tianjin Chest Hospital under the protocol number 2015-006-05 567